|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
ZBTB7A Mediates the Transcriptional Repression Activity of the Androgen Receptor in Prostate Cancer.
|
31444154 |
2019 |
|
Malignant neoplasm of prostate
|
0.340 |
Biomarker
|
disease |
BEFREE |
Therefore, an RNAi-targeted Pokemon gene strategy could be a potential approach to prostate cancer therapy.
|
23374847 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
Notably, we found that ZBTB7A is genetically lost, as well as downregulated at both the mRNA and protein levels, in a subset of human advanced prostate cancers.
|
23727861 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
Therapeutic
|
disease |
CTD_human |
Notably, we found that ZBTB7A is genetically lost, as well as downregulated at both the mRNA and protein levels, in a subset of human advanced prostate cancers.
|
23727861 |
2013 |
|
Malignant neoplasm of prostate
|
0.340 |
AlteredExpression
|
disease |
BEFREE |
High expression of LRF suggests that it may have a potential role in the pathogenesis of both BPH and prostate cancer.
|
21251909 |
2011 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
We identified ASXL2 (34.1%) and ZBTB7A (9.8%) mutations in only AML patients with t(8;21).
|
30251205 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
Biomarker
|
disease |
CTD_human |
Outside of signaling alterations, RUNX1-RUNX1T1 and CBFB-MYH11 AMLs demonstrated remarkably different spectra of cooperating mutations, as RUNX1-RUNX1T1 cases harbored recurrent mutations in DHX15 and ZBTB7A, as well as an enrichment of mutations in epigenetic regulators, including ASXL2 and the cohesin complex.
|
27798625 |
2016 |
|
Leukemia, Myelocytic, Acute
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
The specific association of ZBTB7A mutations with t(8;21) rearranged AML points towards leukaemogenic cooperativity between mutant ZBTB7A and the RUNX1/RUNX1T1 fusion.
|
27252013 |
2016 |
|
Glioblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Resveratrol Represses Pokemon Expression in Human Glioma Cells.
|
25875864 |
2016 |
|
Acute Myeloid Leukemia, M1
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of core-binding factor acute myeloid leukemias.
|
27798625 |
2016 |
|
Giant Cell Glioblastoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Resveratrol Represses Pokemon Expression in Human Glioma Cells.
|
25875864 |
2016 |
|
Glioblastoma Multiforme
|
0.300 |
Biomarker
|
disease |
CTD_human |
Resveratrol Represses Pokemon Expression in Human Glioma Cells.
|
25875864 |
2016 |
|
Acute Myeloid Leukemia (AML-M2)
|
0.300 |
Biomarker
|
disease |
CTD_human |
The genomic landscape of core-binding factor acute myeloid leukemias.
|
27798625 |
2016 |
|
Prostatic Neoplasms
|
0.300 |
Therapeutic
|
group |
CTD_human |
Zbtb7a suppresses prostate cancer through repression of a Sox9-dependent pathway for cellular senescence bypass and tumor invasion.
|
23727861 |
2013 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In cancer, LRF/ZBTB7A has been reported to act either as oncogenic or as oncosuppressive factor by affecting specific cell processes (proliferation, apoptosis, invasion, migration, metastasis, etc) in opposed ways, depending on cancer type and molecular interactions.
|
31823818 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
It has been generally confirmed that zinc finger and BTB domain containing 7A (ZBTB7A) plays an important role in the occurrence and progression of malignant tumours, but the promotion or inhibition effect is related to tumour type.
|
31385585 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Due to the function of ZBTB7A in ER-α positive breast cancer incompletely known, we aimed to determine the role of ZBTB7A in ER-α positive cancer and explore the underlying mechanisms.
|
31715186 |
2019 |
|
Red Blood Cell Count measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Here we characterize a new circRNA (circPOK) encoded by the Zbtb7a gene (also kown as POKEMON, LRF) in the context of mesenchymal tumor progression. circPOK functions as a non-coding proto-oncogenic RNA independently and antithetically to its linear transcript counterpart, which acts as a tumor suppressor by encoding the Pokemon transcription factor.
|
31209250 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally, in vivo tumour transplantation model in nude mice was established to verified the effect of ZBTB7A on metastasis of breast cancer MDA-MB-231 cells.
|
31385585 |
2019 |
|
Finding of Mean Corpuscular Hemoglobin
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Second, we overexpressed the ZBTB7A in MCF-7 cells and silenced the ZBTB7A in MDA-MB-231 cells using lentivirus transfection technology, respectively, and verified the effect of ZBTB7A on migration and invasion of breast cancer cell lines through in vitro cell function experiments, such as wound-healing assay, migration and invasion assay, quantitative real time reverse transcriptase (qRT-PCR) and western blot.
|
31385585 |
2019 |
|
Tumor Cell Invasion
|
0.100 |
PosttranslationalModification
|
phenotype |
BEFREE |
The silencing of ZBTB7 suppressed the proliferation and invasion of renal cancer cells.
|
29673422 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Meta-analysis of genome-wide association studies for body fat distribution in 694 649 individuals of European ancestry.
|
30239722 |
2019 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |